Owkin

OWKIN is pioneering the first Biological Artificial Super Intelligence (BASI) to decode biology and develop tailored solutions for every patient. At the core of this innovation is OWKIN K, a next-generation agentic operating system that seamlessly connects multimodal patient data from top hospitals worldwide to AI agents that co-pilot tasks across biology, drug discovery, and diagnostics. Leveraging this ecosystem, OWKIN is launching new industry verticals led by AI agents, starting with Therakin (a next-gen ASI-driven pharma), OWKIN Dx (ASI-powered diagnostics), and BioOptimus (a foundation model for biology).

Owkin group has raised over $400 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).